Dexrazoxane Kit
Product Images NDC 55150-437

The text describes a figure (Figure 1) showing a comparison between patients treated with FAC and FAC/DEXRAZOXANE in terms of cumulative number of patients on treatment, with at least seven courses of treatment. The horizontal axis shows the cumulative dose of Doxorubicin (measured in mg/m?) and the vertical axis shows the treatment groups (FAC and FAC/DEXRAZOXANE) with a range from 0 to 120. The figure also includes a scatter plot with the number of patients at different cumulative doses of doxorubicin.*

This is a prescription drug called Dexrazoxane, which comes in the form of a lyophilized powder that needs to be reconstituted with 25mL of sodium lactate injection, USP. Each vial contains 250mg of Dexrazoxane hydrochloride and needs to be stored between 20 to 25°C (68 to 77°F). The pH of the solution is adjusted with hydrochloric acid. Reconstituted solutions are stable for 6 hours at controlled room temperature or under refrigeration. This drug is for intravenous use only, and unused solutions should be discarded. For more information on dosage, consult the packaging. This drug was manufactured in India for AuroMedics Pharma LLC.*

This is a prescription-only drug with a National Drug Code (NDC) of 55150-433.01. It should not be used to treat lactic acidosis. It is a solution of 0.167 molar (M/6) sodium lactate and is intended for drug dilution use only. Each milliliter of the solution contains 18.7 mg of sodium lactate, and sodium hydroxide or hydrochloric acid can be added for pH adjustment. The usual dosage is indicated in the accompanying instructions. It comes in a 25-milliliter single-dose vial and should be stored at 20° to 25°C (68° to 77°F). The expiry date is 2021.*

This text is describing a medication called Dexrazoxane for Injection, along with Sodium Lactate Injection. They are single-dose vials that are meant to be used intravenously only. Each vial of Dexrazoxane contains 250mg of the active ingredient, and the pH of the solution is adjusted with hydrochloric acid. The sodium lactate injection vial contains 25mL of fluid and is added to the Dexrazoxane vial to reconstitute the solution. The resulting solution is stable for 6 hours at room temperature or under refrigeration. The text also provides information on storage conditions, manufacturer, and NDC codes.*

Dexrazoxane is a sterile, pyrogen-free lyophilizate used for intravenous purposes with a strength of 500 mg per vial. Each vial has Dexazoxane hydrochloride equivalent to 500 mg. The pH of the resultant solution is adjusted using hydrochloric acid (NF) after reconstitution with 0.167M (/6) sodium lactate injection, USP 50 mL vial. The reconstituted solutions remain stable for six hours at controlled room temperature or under refrigeration at 2° to 8°C (36° to 46°F), and any unused solutions must be discarded. The usual dosage information is in the accompanying prescribing document. AuroMedics Pharma LLC manufactured it and is available for prescription only. The given code number is AP/DRUGS/103/97.*

This is information about a medication called Sodium Lactate Injection, USP provided by AuroMedics. This medication is only for drug diluent use and is provided in a single-dose vial size of 50mL. It is sterile and should be stored at room temperature. It should not be used to treat lactic acidosis. Each mL contains 18.7mg of sodium lactate and may include sodium hydroxide and/or hydrochloric acid for pH adjustment. There is no information on what this medication is used for, or its common side effects.*

This is a medication package of Dexrazoxane for Injection, with a strength of 500 mg per vial, and 0.167M (M/6) Sodium Lactate Injection, USP as diluent. The package includes a single-dose vial of dexrazoxane and 50 mL vial of sodium lactate injection as a diluent. The product is for intravenous use only, is sterile, and pyrogen-free lyophilizate. The package also includes prescribing information, dosage, and storage instructions. This medication is distributed by AuroMedics Pharma LLC and is made in India.*